Minocycline/disodium edetate/ethyl alcohol - Citius Pharmaceuticals

Drug Profile

Minocycline/disodium edetate/ethyl alcohol - Citius Pharmaceuticals

Alternative Names: HEAL solution; Mino-Lok Therapy (MLT); Mino-Lok™; Minocycline-EDTA-EtOH

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Citius Pharmaceuticals Inc; Leonard Meron Biosciences; University of Texas M. D. Anderson Cancer Center
  • Class Anti-infectives; Antibacterials; Anticoagulants; Antiseptics; Disinfectants; Small molecules; Tetracyclines
  • Mechanism of Action Chelating agents; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Catheter infections

Most Recent Events

  • 07 Nov 2017 Phase-II clinical trials in Catheter infections in Lebanon, Japan, Brazil before November 2017
  • 07 Nov 2017 Efficacy data from a phase IIb trial in Catheter infections released by Citius Pharmaceuticals
  • 31 Oct 2017 Minocycline/disodium edetate/ethyl alcohol - Citius Pharmaceuticals receives Fast Track designation for Catheter infections [Liquid] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top